Peter Marschel
Chief Business Officer
Bio:
Mr. Marschel, MSA, MBA, has been Decoy's Chief Business Officer since he co-founded the company in 2020. Since then Decoy (Nasdaq: DCOY) has built its IMP³ACT platform and is pioneering a new category of antivirals called Designable Multi-Antivirals (D-MAVs): single drugs designed to target viral mechanisms conserved across multiple virus families, with both commercial and public health applications. Decoy's work has been supported by grants from the Gates Foundation, Google, and NVIDIA. Until April 2020, Mr. Marschel was co-founder and Chief Financial Officer of PercepTx, a targeted cancer immunotherapy accelerator focused on using computational modeling and quantitative pharmacology to rapidly increase the value of preclinical monoclonal antibody-based therapeutic assets. Prior to that he served in a range of business development, analytics, and commercial roles at Merck, Vertex Pharmaceuticals, and Takeda Pharmaceuticals, including leading market analytics for the cystic fibrosis franchise at Vertex Pharmaceuticals.